Y-mabs therapeutics, inc. announces update on omburtamab in dsrct

Y-mabs therapeutics, inc. announced a clinical update on omburtamab for desmoplastic small round cell tumor (“dsrct”). dsrct is an aggressive malignancy that typically presents as intraabdominal sarcomatosis in young males. less than 100 patients are diagnosed each year in the us, and given this incidence, optimal treatment has not yet been defined. patients with dsrct have a very poor prognosis with limited five year survival. even for those patients where gross total resection (“gtr”) is possible, five year overall survival (“os”) appears to be approximately 20%. based on observations from msk, whole abdominalpelvic intensity-modulated radiotherapy (“wa-imrt”) may be advisable for all patients whose tumor can be resected. the data presented at ctos indicates that adding ip-rit with iodinated omburtamab to the standard wa-imrt treatment appears to be well tolerated. furthermore, adding omburtamab ip-rit to gtr improved the five year kapplan meier estimated os from a historical rate of approximately 20% to approximately 40%.
YMAB Ratings Summary
YMAB Quant Ranking